SS31 Peptide: 2026 Research Data Reveals Breakthroughs in Mitochondrial Therapy and Industry Growth
Abstract: SS31 peptide, a mitochondrial-targeted antioxidant, demonstrates breakthrough efficacy in 2026 research for mitochondrial dysfunction disorders. Composed of D-arginine and aromatic residues, it enhances ATP production and reduces oxidative stress. Industry growth is driven by expanding applications in neurodegenerative and metabolic diseases. Comparative studies show superior mitochondrial uptake over MitoQ. Selection guidelines prioritize purity (>98%) and stability. Emerging data supports its therapeutic potential, positioning SS31 as a key player in mitochondrial therapy innovation.